The Japanese PV device market will see modest growth through 2029, driven primarily by the expanding PAD population and the availability of new premium-priced products. However, market revenues will be hindered by the impact of COVID-19 pandemic and ASP declines caused by biennial reimbursement cuts by the MHLW over the forecast period .
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for PV devices in Japan across a 10-year period.
The COVID-19 pandemic will have a minimal impact on overall PV procedures and revenues in 2020.
What factors will contribute to the impact on the PV device market?
To what degree will the pandemic affect different PV device segments?
How soon will procedure volumes, sales, and revenues recover over the forecast period?
A meta-analysis was published in 2018 that showed an increased risk of death associated with paclitaxel-coated balloons and stents.
How has this study impacted the Japanese market for DCBs and DES?
How has this study impacted physicians' perception of these products?
Which companies will be affected and how?
What strategies are the concerned companies employing to counteract the effects of the study?
Various DCB and DES manufacturers have invested in clinical trials to expand their offerings in indications such as BTK.
Which trials will impact the adoption of DCBs and DES for the BTK indication?
What has been physicians' preferred approach to treat lesions in the BTK indication?
Premium-priced DCBs for lower extremities have entered the Japanese market and will drive market growth.
Will DCBs or DES become the standard drug-eluting solution for BTK lesions?
Which competitors are likely to enter the DCB market, and which will gain the most market share?
How will DCB uptake affect use of other PV devices, such as stents and standard balloon catheters?
Which new indications will drive growth in the DCB market?
Biennial reimbursement cuts by the MHLW continue to affect the Japanese PV device market.
Which market segments will experience the highest cuts to reimbursement, and why?
In which segments will procedural growth compensate for ASP declines, resulting in market growth?
What are alternative strategies for companies to encourage adoption of premium-priced products?
- Peripheral Vascular Devices - Market Insights - Japan
Author(s): Bishwjit Ghoshal, MBA
Bishwjit Ghoshal is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.
Follow Bishwjit on twitter: @Bishwjit_DRG